Vulcan Value Partners LLC Sells 357,732 Shares of IQVIA Holdings Inc. $IQV

Vulcan Value Partners LLC reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 52.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 323,201 shares of the medical research company’s stock after selling 357,732 shares during the quarter. IQVIA comprises approximately 1.3% of Vulcan Value Partners LLC’s holdings, making the stock its 21st biggest position. Vulcan Value Partners LLC’s holdings in IQVIA were worth $72,852,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in IQVIA by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after acquiring an additional 159,899 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of IQVIA by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after acquiring an additional 24,453 shares in the last quarter. Boston Partners boosted its position in shares of IQVIA by 14.9% during the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock valued at $923,276,000 after acquiring an additional 530,672 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 16.2% in the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after purchasing an additional 528,753 shares in the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of IQVIA by 1.2% in the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after purchasing an additional 41,643 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.2%

IQV opened at $168.14 on Friday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market cap of $28.06 billion, a price-to-earnings ratio of 20.84, a PEG ratio of 1.44 and a beta of 1.21. IQVIA Holdings Inc. has a 12 month low of $153.01 and a 12 month high of $247.04. The stock has a fifty day moving average price of $173.63 and a 200-day moving average price of $191.68.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has approved a stock repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Wall Street Analyst Weigh In

Several brokerages have weighed in on IQV. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. HSBC set a $210.00 target price on IQVIA in a research report on Wednesday, June 3rd. Finally, Royal Bank Of Canada initiated coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $222.56.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.